IGF2BP3–FZD1/7 Regulation Underpins Cancer Stemness and Carboplatin Resistance in Triple-Negative Breast Cancer

Study Background and Research Question

Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Treatment options for TNBC are limited, with conventional chemotherapy—most notably platinum-based agents such as carboplatin—serving as the therapeutic mainstay. Despite initial responsiveness, a significant fraction of TNBC patients develop resistance and relapse, often attributed to the persistence of cancer stem-like cells (CSCs). These CSCs possess self-renewal and tumor-initiating capabilities, which promote chemoresistance and tumor recurrence. The molecular mechanisms that maintain CSC populations and drive carboplatin resistance in TNBC, however, remain incompletely understood.

Key Innovation from the Reference Study

The reference study (Cai et al., 2025) introduces a new mechanistic axis linking the m6A reader protein IGF2BP3 to the stabilization of FZD1/7 mRNAs, thereby promoting CSC properties and resistance to carboplatin. This work is among the first to delineate how post-transcriptional m6A modifications—specifically, the action of IGF2BP3 in recognizing and stabilizing methylated FZD1/7 transcripts—directly sustain β-catenin signaling and enhance stemness in TNBC. The demonstration that pharmacological inhibition of FZD1/7 can restore carboplatin sensitivity further underscores the translational impact of these findings.

Methods and Experimental Design Insights

The investigators used a multi-layered experimental approach to unravel the IGF2BP3–FZD1/7 axis in TNBC:

• Transcriptomic Analysis: Mining the TCGA-BRCA dataset revealed IGF2BP3 enrichment in TNBC stem-like subpopulations.
• Cell Sorting and Validation: FACS was employed to isolate CSC-enriched (CD24−/CD44+) fractions from TNBC cell lines, confirming elevated IGF2BP3 expression.
• Loss-of-Function Studies: siRNA-mediated knockdown of IGF2BP3 in TNBC-CSCs led to significant reductions in stemness markers and increased sensitivity to carboplatin.
• RNA Immunoprecipitation (RIP): IGF2BP3 was shown to directly bind to the 3′UTRs of FZD1 and FZD7 mRNAs in an m6A-dependent manner.
• Pathway Activation Assays: Stabilization of FZD1/7 enhanced β-catenin nuclear translocation and activity, underpinning stem-like phenotypes.
• Small-Molecule Inhibition: Treatment with Fz7-21, an FZD1/7 antagonist, disrupted CSC maintenance and synergized with carboplatin to induce TNBC cell death.
• Homologous Recombination Repair (HRR) Assays: Both IGF2BP3 knockdown and Fz7-21 impaired HRR, a key mechanism of platinum resistance.

Core Findings and Why They Matter

Key results from the study include:

• IGF2BP3 as a Dominant m6A Reader: Enriched in TNBC-CSCs, IGF2BP3 is essential for maintaining stem-like traits and mediates resistance to carboplatin.
• m6A-Dependent Stabilization of FZD1/7: IGF2BP3 binds m6A-methylated FZD1/7 transcripts, elevating their stability and promoting receptor heterodimerization.
• β-Catenin Pathway Activation: This stabilization facilitates β-catenin nuclear translocation, a hallmark of CSC maintenance and expansion.
• Resistance Mechanism Elucidated: The IGF2BP3–FZD1/7 axis enhances homologous recombination repair, directly conferring resistance to platinum-based chemotherapy.
• Pharmacological Targeting: Inhibition of FZD1/7 (with Fz7-21) phenocopies IGF2BP3 knockdown, abrogates stemness, impairs HRR, and synergistically sensitizes CSCs to carboplatin-induced cytotoxicity.
• Direct Binding Sites Mapped: The study mapped the precise IGF2BP3–FZD1/7 mRNA interaction sites, paving the way for rational design of RNA-binding protein inhibitors.

These findings underscore the importance of the IGF2BP3–FZD1/7–β-catenin pathway in sustaining both stemness and chemotherapy resistance. Targeting this axis provides a rationale for combinatorial regimens that could lower required carboplatin doses and reduce associated toxicity in TNBC management.

Comparison with Existing Internal Articles

Several recent reviews and research highlights have explored the implications of platinum-based DNA synthesis inhibitors in oncologic models:

• The article "Carboplatin in Preclinical Oncology: Decoding DNA Damage..." discusses carboplatin's multifaceted impact on DNA repair pathways and the challenge of stem-like cell resistance. While it emphasizes carboplatin's potent DNA damage induction, the reference study provides direct mechanistic evidence linking m6A-modified RNA regulation to carboplatin resistance, moving beyond descriptive observations to actionable targets.
• "IGF2BP3–FZD1/7 Axis Drives Carboplatin Resistance in TNBC" similarly highlights this signaling axis but lacks the detailed experimental mapping of IGF2BP3–FZD1/7 mRNA interactions and the demonstration of pharmacological synergy between Fz7-21 and carboplatin as shown in the present study.
• The discussion in "Harnessing Carboplatin’s Mechanistic Leverage: Strategic..." aligns with the reference paper's strategy of combining platinum-based DNA synthesis inhibitors with agents targeting CSC-specific pathways but stops short of providing structural or direct binding evidence for new inhibitor development.

Thus, the current reference paper distinguishes itself by providing both a mechanistic and structural foundation for future drug development targeting CSCs in TNBC.

Limitations and Transferability

Despite its strengths, the study's findings are subject to several limitations:

• Preclinical Nature: Most experiments were conducted in cell lines and xenograft models; clinical validation in patient-derived samples or trials remains outstanding.
• Narrow Cancer Subtype Focus: The IGF2BP3–FZD1/7 axis was characterized specifically in TNBC contexts; its relevance in other cancer types or non-stem-like cell populations is not fully established.
• Potential Resistance Mechanisms: While targeting FZD1/7 sensitizes CSCs to carboplatin, other compensatory pathways could emerge upon dual inhibition, meriting further investigation.

Transferability to broader oncology workflows will depend on the conservation of this regulatory axis in other tumor contexts and the tolerability of combined pharmacological interventions.

Protocol Parameters

• CSCs enrichment strategy: Isolate CD24−/CD44+ subpopulations from TNBC cell lines using FACS for functional assays.
• IGF2BP3 knockdown: Employ siRNA oligonucleotides (typically 25–50 nM) for 48–72 hours to suppress IGF2BP3 expression prior to carboplatin exposure.
• Carboplatin treatment: Treat TNBC-CSCs with carboplatin at concentrations ranging from 2.2 to 116 μM for 24–72 hours, per product literature and compound guidelines.
• Fz7-21 co-treatment: Apply Fz7-21 at empirically determined concentrations (e.g., 2–10 μM) concomitant with carboplatin to assess synergistic cytotoxicity and impairment of HRR.
• β-catenin activity assay: Use nuclear translocation of non-phosphorylated β-catenin (Ser37/Thr41) as a readout for pathway activation.
• RNA immunoprecipitation (RIP): Perform RIP to confirm direct IGF2BP3–FZD1/7 mRNA binding in the presence and absence of m6A methylation (modulate with RBM15 knockdown or m6A inhibitors as controls).

Research Support Resources

For researchers aiming to replicate or extend these findings, Carboplatin (SKU A2171) from APExBIO is a well-characterized platinum-based DNA synthesis inhibitor with proven activity in preclinical oncology research, including ovarian carcinoma and lung cancer models. Its application in cell proliferation and cytotoxicity assays aligns with the workflows described in this and related studies. Detailed handling and solubility guidance are available in the product documentation, supporting robust and reproducible experimental design.